

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 24 May 2022, with regard to the number and election of members of the board of directors.

The committee proposes seven members of the board of directors and no deputy directors.

The committee proposes that Erika Kjellberg Eriksson, Mats Nilsson, Marianne Hansson, Mario Gualano, Per-Olof Wallström and Hans Johansson be re-elected as board members and that Nina Korfu-Pedersen be elected as new board member, each for a term of office until the end of the next annual general meeting. Furthermore, the committee proposes Erika Kjellberg Eriksson to be re-elected as chairperson of the board of directors.

Marcus Storch has informed the nomination committee that he is not available for re-election.

Nina Korfu-Pedersen, born 1973, is currently Chief Transformation Officer for control & staff functions at SEB where she also has had roles as SEB's CFO and global manager for operations & staff functions with a managerial responsibility for 2,500 employees. She has long experience of leading major change initiatives globally, operationally and strategically in different industries and roles, both in the consulting industry and in line manager roles. She has more than 15 years of experience in international leadership roles. Nina holds a master exam from Handelshöyskolen BI (Norway) and a Master of Arts in International Relations from University of Reading (UK). Nina Korfu-Pedersen is independent in relation to the company, the company's executive management and its major shareholders.

Information about all persons proposed as members of the board of directors of Q-linea, the nomination committee's motivated statement regarding the proposal for the board of directors and the nomination committee's complete proposal will be available on Q-linea's website, www.qlinea.com in connection with the issuance of the notice to attend the annual general meeting 2022, which is expected to be published around week 17.

The nomination committee has been appointed according to the principles adopted by the annual general meeting 2021 and consists of Öystein Engebretsen (Investment AB Öresund, chairperson of the nomination committee), Erika Kjellberg Eriksson (Nexttobe AB, chairperson of the board) and Ulrik Grönvall (Swedbank Robur Fonder).

Uppsala, April 2022

The nomination committee of Q-linea AB (publ)



For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com +46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB Anders.Lundin@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar[®] is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

The proposal by the nomination committee of Q-linea AB (publ) for election of members of the board of directors